277 related articles for article (PubMed ID: 15720184)
21. The mdm2 proto-oncogene.
Haines DS
Leuk Lymphoma; 1997 Jul; 26(3-4):227-38. PubMed ID: 9322885
[TBL] [Abstract][Full Text] [Related]
22. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function.
Thomas A; White E
Genes Dev; 1998 Jul; 12(13):1975-85. PubMed ID: 9649502
[TBL] [Abstract][Full Text] [Related]
23. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
24. Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development.
Zhang Q; He X; Chen L; Zhang C; Gao X; Yang Z; Liu G
J Pathol; 2012 Nov; 228(3):416-28. PubMed ID: 22821713
[TBL] [Abstract][Full Text] [Related]
25. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
26. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
27. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
28. p53-independent functions of the p19(ARF) tumor suppressor.
Weber JD; Jeffers JR; Rehg JE; Randle DH; Lozano G; Roussel MF; Sherr CJ; Zambetti GP
Genes Dev; 2000 Sep; 14(18):2358-65. PubMed ID: 10995391
[TBL] [Abstract][Full Text] [Related]
29. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
Chène P
Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
[TBL] [Abstract][Full Text] [Related]
31. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation.
Bergamaschi D; Samuels Y; Zhong S; Lu X
Oncogene; 2005 May; 24(23):3836-41. PubMed ID: 15782125
[TBL] [Abstract][Full Text] [Related]
32. p53-independent functions of MDM2.
Ganguli G; Wasylyk B
Mol Cancer Res; 2003 Dec; 1(14):1027-35. PubMed ID: 14707286
[TBL] [Abstract][Full Text] [Related]
33. MDM2 and prognosis.
Onel K; Cordon-Cardo C
Mol Cancer Res; 2004 Jan; 2(1):1-8. PubMed ID: 14757840
[TBL] [Abstract][Full Text] [Related]
34. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
35. Mdm-2: "big brother" of p53.
Momand J; Zambetti GP
J Cell Biochem; 1997 Mar; 64(3):343-52. PubMed ID: 9057092
[No Abstract] [Full Text] [Related]
36. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
Hernandez I; Maddison LA; Wei Y; DeMayo F; Petras T; Li B; Gingrich JR; Rosen JM; Greenberg NM
Mol Cancer Res; 2003 Dec; 1(14):1036-47. PubMed ID: 14707287
[TBL] [Abstract][Full Text] [Related]
38. mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells.
Bull EK; Chakrabarty S; Brodsky I; Haines DS
Oncogene; 1998 Apr; 16(17):2249-57. PubMed ID: 9619834
[TBL] [Abstract][Full Text] [Related]
39. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
